Centre Atenció Primaria Consell de Cent, Àmbit Barcelona Ciutat, Barcelona, Spain.
Am Heart J. 2011 Sep;162(3):444-50. doi: 10.1016/j.ahj.2011.06.017. Epub 2011 Aug 11.
We sought to analyze the trends in first Q-wave acute myocardial infarction (AMI) case fatality from 1978 to 2007 in a population-based hospital register, to determine the variables related to these changes, and to assess the effectiveness of current AMI management.
Population-based hospital registry included patients with first Q-wave AMI aged 25 to 74 years admitted between 1978 and 2007. Sociodemographic and clinical characteristics, treatments, and procedures used during hospital stay, and 28-day case fatality were recorded. Logistic regression was used for multivariate analysis of six 5-year periods.
The 30-year study included 3,982 patients. Mean 28-day case fatality was 8.96%, with a decreasing trend from 16.6% in the first 5-year period to 4.7% in the sixth (P for trend < .001). Study period was independently associated with case fatality. Case-fatality reduction attributable to pharmacologic treatments was 51% overall; in 24-hour survivors, pharmacologic treatments and broad use of invasive procedures explained 39% and 38%, respectively, of the difference between the observed case fatality in 2003-2007 and 1978-1982.
A dramatic decrease in 28-day case fatality occurred during this 30-year period and was mainly related to the use of antiplatelet drugs, β-blockers, thrombolysis, and invasive procedures. These data support the current guidelines for the management of acute coronary syndrome.
我们旨在分析从 1978 年至 2007 年基于人群的医院登记处中首次 Q 波急性心肌梗死(AMI)病例死亡率的趋势,确定与这些变化相关的变量,并评估当前 AMI 管理的效果。
基于人群的医院登记处纳入了 1978 年至 2007 年期间入院的年龄在 25 至 74 岁之间的首次 Q 波 AMI 患者。记录社会人口统计学和临床特征、住院期间的治疗和程序以及 28 天病例死亡率。使用逻辑回归对六个 5 年时间段进行多变量分析。
这项为期 30 年的研究共纳入 3982 名患者。28 天病例死亡率平均为 8.96%,呈下降趋势,从第一个 5 年期间的 16.6%降至第六个 5 年期间的 4.7%(趋势 P<0.001)。研究期间与病例死亡率独立相关。药物治疗归因于病例死亡率降低了 51%;在 24 小时幸存者中,药物治疗和广泛使用介入程序分别解释了 2003-2007 年和 1978-1982 年观察到的病例死亡率之间差异的 39%和 38%。
在这 30 年期间,28 天病例死亡率显著下降,主要与抗血小板药物、β受体阻滞剂、溶栓和介入程序的使用有关。这些数据支持急性冠状动脉综合征的当前管理指南。